Evidence map›Paper›PMID 41246553›Full record

ArticleOncology letters2026

Long non-coding RNA RP11-196G11.6 inhibits neuroblastoma progression by regulating the miR-376a-3p/RYBP signaling axis.

Jie Zhang, Kai Huang, Jianwu Zhou, Wenge Liao, Fei Li, Zhenzhen Zhao, Shan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie ZhangDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.
Kai HuangDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.
Jianwu ZhouDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.
Wenge LiaoDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.
Fei LiDepartment of Pediatric Surgery, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China.
Zhenzhen ZhaoDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.
Shan WangDepartment of Pediatric Surgical Oncology, The Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are emerging as key regulators of neuroblastoma (NB) progression; however, their interplay with MYCN-driven mechanisms remains to be elucidated. The present study aimed to characterize the expression profile of lncRNA RP11-196G11.6 in NB, and to further explore its functional role and mechanism in the pathogenesis of this disease. Transcriptomics data from NB and disseminated tumor cell (DTC) samples (Gene Expression Omnibus; accession no. GSE94035) were analyzed via principal component analysis (PCA), differential expression analysis and CIBERSORT immune profiling. The biological function was assessed using gain- and loss-of-function experiments in IMR-32 (MYCN

Indexed as

epithelial-mesenchymal transitionlong non-coding RNAMYCNneuroblastomaRP11-196G11.6

Identifiers

PMID41246553
PMCPMC12612797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.